The Phase II contract is for the further development of a portable multiplexed immunoassay system that would deliver a panel of host response biomarker results.
The five-year federal supply contract is for the company's Steripath Initial Specimen Diversion Device, which virtually eliminates blood culture contamination.
The proposed diagnostic platform will be able to identify and determine resistance of bloodstream infections within three hours.
The immunochromatographic approach detects not only the presence of a substance in a sample, but its amount by visualizing its concentration using gold nanoparticles.
Running on the Biocartis Idylla platform, Immunexpress' Septicyte test will detect sepsis in patients in as little as an hour.
In the longer term, the two firms plan to use PlexBio's multiplexing technology to develop a full menu of infectious disease assays.
Biocartis will help develop and commercialize Immunexpress' Septicyte test to run on the Idylla platform.
Its CEO said that although a hospital screening test for sepsis is a focus, a fever test that informs about antibiotic use could be available sooner.
At the JPM Healthcare Conference on Wednesday, its CEO also said that lower-than-anticipated revenues in Q4 2017 were due to a longer-than-expected sales cycle.
The sepsis diagnostics market heated up during the year, with FDA clearances for a handful of tests, growing investor interest, and R&D advances in the field.